Health Care·Biotechnology·$10.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.22 | N/A | -1.38% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.22 | N/A | -1.38% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current performance but remains focused on future objectives. They did not provide specific guidance for upcoming quarters.
Management highlighted ongoing challenges in meeting financial expectations.
They emphasized their focus on long-term goals despite short-term setbacks.
This earnings report indicates that Arrowhead Pharmaceuticals is still facing challenges, particularly with its earnings per share. Despite the miss on EPS, the stock saw a slight increase of 1.17%, possibly due to investor optimism about the company's long-term strategies. The lack of revenue figures and guidance may leave some investors cautious moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
H WORLD GROUP LIMITE ADR
Aug 11, 2014